A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07915791
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pulmonary Disease, Chronic Obstructive
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- November 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- GSK Investigational Site · Newport Beach, CA
Florida · 1
- GSK Investigational Site · Miami, FL
Kansas · 1
- GSK Investigational Site · Derby, KS
Maryland · 1
- GSK Investigational Site · Columbia, MD
Oklahoma · 1
- GSK Investigational Site · Oklahoma City, OK
Pennsylvania · 1
- GSK Investigational Site · Philadelphia, PA
South Carolina · 1
- GSK Investigational Site · Rock Hill, SC
Texas · 1
- GSK Investigational Site · Tomball, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.